Account
Inquiry
Tirzepatide 15mg is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist currently being developed for type 2 diabetes treatment and weight management applications. This pharmaceutical grade peptide demonstrates superior efficacy in glucose control and weight reduction compared to single agonists.
Clinical trials have shown remarkable results with tirzepatide 15mg, including average weight loss of 20.9% after 72 weeks of treatment. The dual agonist mechanism provides enhanced metabolic effects by simultaneously activating both GIP and GLP-1 pathways, making it particularly effective for metabolic disorders.
Structurally, tirzepatide 15mg features a modified lysine side chain with PEGylation, which significantly improves the peptide's water solubility and stability. This modification contributes to its extended half-life, allowing for convenient once-weekly dosing in clinical applications.
Our tirzepatide 15mg is produced under strict quality control standards, ensuring 99.9% purity as confirmed by HPLC analysis. The white powder is carefully packaged to maintain stability and purity throughout storage and transportation.
As a research chemical, tirzepatide 15mg offers scientists a valuable tool for studying metabolic pathways and developing new therapeutic approaches for diabetes and obesity. The compound has received FDA Fast Track designation, highlighting its potential clinical significance.
Storage recommendations for tirzepatide 15mg include keeping the product in a cool, dry environment protected from light. Avoid repeated freeze-thaw cycles and prolonged exposure to air to maintain optimal stability of the peptide powder.
For research use only. Not for human consumption. This product is intended solely for laboratory research purposes by qualified professionals.
